Genzyme Announces Agreement to Sell Diagnostics Business
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash.
Pfizer Launches Global Centers for Therapeutic Innovation
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers.
Roche announces implementation plans for its Operational Excellence Program
- Details
- Category: Roche
Roche disclosed the measures it plans to take as part of its Group-wide Operational Excellence Program, announced in September. The initiative is a response to mounting cost pressures in healthcare - particularly in the US and Europe - and to increasing hurdles for the approval and pricing of new medicines.
Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim employees across the globe were called to action in support of this year's World Diabetes Day. Equipped with pedometers for a week, each step taken by employees was counted and converted into a contribution of 15.000 Euros in support of the International Diabetes Federation's (IDF) "Life for a Child" Programme.
Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization for patients with chronic heart failure with mild symptoms treated with Inspra® (eplerenone) versus those given placebo in addition to standard HF therapy.
Rivaroxaban Significantly Reduces Risk of Stroke with Comparable Safety versus Warfarin
- Details
- Category: Bayer
Bayer announced the results from the pivotal, double-blind Phase III, ROCKET AF trial. In the study, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF).
Diabetes awareness survey reveals alarming figures across the Middle East and Northern Africa regions
- Details
- Category: Novo Nordisk
In the lead up to World Diabetes Day 2010 on 14 November Novo Nordisk and Ipsos Emirates Health conducted a survey in ten countries of the Middle East and Northern Africa (MENA) region: Algeria, Egypt, Iran, Iraq, Jordan, Lebanon, Morocco, Kingdom of Saudi Arabia (KSA), Tunisia and the United Arab Emirates (UAE).
More Pharma News ...
- Collaboration of Boehringer Ingelheim and VTU Technology
- Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis
- Nycomed is keeping the pace in third quarter 2010
- Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent
- Roche reports promising Phase II results with new targeted approach in advanced melanoma
- Genzyme Responds to Sanofi-Aventis Letter
- Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions